Teacher Retirement System of Texas Increases Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Teacher Retirement System of Texas boosted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 18.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 28,159 shares of the biopharmaceutical company’s stock after buying an additional 4,328 shares during the quarter. Teacher Retirement System of Texas’ holdings in Intra-Cellular Therapies were worth $2,352,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. True Wealth Design LLC acquired a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth approximately $32,000. GAMMA Investing LLC increased its stake in Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Intra-Cellular Therapies in the fourth quarter valued at $96,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at $97,000. Finally, Quarry LP grew its holdings in shares of Intra-Cellular Therapies by 260.0% during the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,300 shares during the period. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Thursday, March 20th. They issued a “hold” rating on the stock. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price objective for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Ten analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Hold” and a consensus price target of $106.08.

Intra-Cellular Therapies Stock Performance

ITCI stock opened at $131.69 on Thursday. The company’s 50 day moving average price is $128.89 and its 200 day moving average price is $98.82. The firm has a market capitalization of $14.00 billion, a price-to-earnings ratio of -151.37 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.79.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.